Whipplewood Advisors’s Biogen BIIB Stock Holding History

Whipplewood Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19	Closed	-$3.48K	–	681
2026 Q1	$3.48K	Buy	+19	New	+$3.5K	﹤0.01%	676
2025 Q3	–	Sell	-32	Closed	-$4.02K	–	394
2025 Q2	$4.02K	Buy	32 +4	+14%	+$498	﹤0.01%	736
2025 Q1	$4.11K	Sell	28 -2	-7%	-$286	﹤0.01%	737
2024 Q4	$4.59K	Buy	+30	New	+$5.06K	﹤0.01%	715

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Whipplewood Advisors's BIIB Position: Q2 2026 in Review

Whipplewood Advisors sold out of Biogen (BIIB) in Q2 2026, closing a stake of 19 shares — an estimated $3.48K sold.

Whipplewood Advisors first reported a position in BIIB in Q4 2024 and held it in 4 quarters. The position peaked at $4.59K in Q4 2024. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Whipplewood Advisors reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Whipplewood Advisors sold 19 Biogen shares in Q2 2026, an estimated $3.48K.
Whipplewood Advisors first reported a position in Biogen in Q4 2024 and held it in 4 quarters.
Whipplewood Advisors's Biogen position peaked at $4.59K in Q4 2024.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.